1)Hauge SH, et al:Oseltamivir-resistant influenza viruses A(H1N1), Norway, 2007-08. Emerg Infect Dis 15:155-162, 2009
2)高橋美保子,永井正規:1987年-2005年のわが国におけるインフルエンザ流行による超過死亡.日衛誌 63:5-19, 2008
3)Thompson WW, et al:Influenza-associated hospitalizations in the United States. JAMA 292:1333-1340, 2004
4)Harper SA, et al:Seasonal influenza in adults and children─diagnosis, treatment, chemoprophylaxis, and institutional outbreak management:clinical practice guidelines of the Infectious Disease Society of America. Clin Infect Dis 48:1003-1032, 2009
5)Kaiser L, et al:Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med 163:1667-1672, 2003
6)Makela MJ, et al:Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza:a randomized, double-blind, placebo-controlled European study. J Infect 40:42-48, 2000
7)Lalezari J, et al:Zanamivir for the treatment of influenza A and B infection in high-risk patients:a pooled analysis of randomized controlled trials. Arch Intern Med 161:212-217, 2001
8)Whitley RJ, et al:Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 20:127-133, 2001
9)Johnston SL, et al:Oral oseltamivir improves pulmonary function and reduces exacerbation frequency for influenza-infected children with asthma. Pediatr Infect Dis J 24:225-232, 2005
10)Kiso M, et al:Resistant influenza A viruses in children treated with oseltamivir:descriptive study. Lancet 364:759-765, 2004
11)Moscona A:Global transmission of oseltamivir-resistant influenza. N Engl J Med 360:953-956, 2009
12)Moscona A:Oseltamivir resistance─disabling our influenza defenses. N Engl J Med 353:2633-2636, 2005